Literature DB >> 31406072

[Refractory eosinophilic gastroenteritis with gastritis, duodenal ulcer, and colitis: a case report].

Yuko Miura1, Fumihiko Iwamoto1, Yasuaki Ishida1, Toru Kuno1, Keisuke Tanaka1, Shoji Kobayashi1, Takashi Yoshida1, Tatsuya Yamaguchi1, Tadashi Sato1, Nobuyuki Enomoto1.   

Abstract

Eosinophilic gastroenteritis is a rare disease that causes various abdominal symptoms that result from the infiltration of eosinophils in the digestive tract. However, this condition has been poorly explored, and the treatment criteria and prognosis after treatment are still unclear. A 20-year-old man with a refractory duodenal ulcer had been undergoing treatment since 14 years of age at another hospital. He was admitted to our hospital with abdominal pain and anemia (hemoglobin:6.3g/dL). His blood test showed elevated serum immunoglobulin E levels, considering that he was allergic to many foods. Furthermore, endoscopic biopsy detected the occurrence of eosinophilic gastroenteritis with gastritis, duodenal ulcer, and colitis. We treated him by avoiding allergenic foods and prescribing antihistamine and vonoprazan;however, duodenal ulcer and gastrointestinal tract inflammation did not show improvement. Thus, he was diagnosed with wide-ranging and refractory eosinophilic gastroenteritis and treated with 40mg/day of steroids. After 2 months, he recovered from gastritis and duodenal ulcer, and his eosinophil level decreased, as assessed using endoscopic biopsy. Eosinophilic gastroenteritis is poorly investigated, and its treatment standards have not yet been determined. Nonetheless, steroid treatment is often applied in severe cases.

Entities:  

Mesh:

Year:  2019        PMID: 31406072     DOI: 10.11405/nisshoshi.116.668

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  1 in total

1.  Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide.

Authors:  Kimitoshi Kubo; Noriko Kimura; Katsuhiro Mabe; Soichiro Matsuda; Momoko Tsuda; Mototsugu Kato
Journal:  Intern Med       Date:  2020-06-15       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.